Mereo BioPharma Group Sued for Securities Law Violations

DJS Law Group Encourages Investors to Discuss Their Rights

Mar. 20, 2026 at 6:23am

Got story updates? Submit your updates here. ›

The DJS Law Group has filed a class action lawsuit against Mereo BioPharma Group plc (NASDAQ: MREO) for violations of federal securities laws. The lawsuit alleges that Mereo made false and misleading statements to investors about the results of its Phase 3 ORBIT and COSMIC clinical programs, which failed to meet their endpoints. Shareholders who purchased Mereo stock during the class period are encouraged to contact the law firm to discuss potential lead plaintiff appointments and recovering their losses.

Why it matters

This lawsuit highlights the importance of transparency and accurate disclosures from public companies. Investors rely on truthful information to make informed decisions, and any misleading statements can lead to significant losses. The outcome of this case could set precedents around corporate accountability and the responsibilities of publicly traded firms.

The details

According to the complaint, Mereo BioPharma Group plc violated sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 by making false and misleading statements about the results of its ORBIT and COSMIC clinical programs. Both programs failed to meet their endpoints against placebo or bisphosphonate control groups, but Mereo allegedly misled investors about the true outcomes.

  • The class period runs from June 5, 2023 to December 26, 2025.
  • The deadline for shareholders to join the case is April 6, 2026.

The players

Mereo BioPharma Group plc

A biopharmaceutical company focused on developing and commercializing innovative therapeutics that address unmet medical needs in oncology and rare diseases.

DJS Law Group

A law firm specializing in securities class actions, corporate governance litigation, and M&A appraisals. The firm represents large hedge funds and alternative asset managers.

Got photos? Submit your photos here. ›

What they’re saying

“Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.”

— David J. Schwartz, DJS Law Group

What’s next

The judge will decide on April 6, 2026 whether to allow shareholders to join the class action lawsuit against Mereo BioPharma Group.

The takeaway

This case underscores the need for public companies to provide accurate and transparent information to investors. Misleading statements about clinical trial results can have serious consequences, both for shareholders who suffer losses and for the companies themselves. The outcome of this lawsuit could set important precedents around corporate accountability and investor protections.